Boston, MA 10/03/2014 (wallstreetpr) – According to reports, Eli Lilly and Co (NYSE:LLY) has decided to stop the development of Tabalumab. It was in phase three Lupus Studies at the time of discontinuation of the production.
Insights of this decision:
As per the information, Eli Lilly and Co (NYSE:LLY) had Tabalumab in order to study the treatment of systemic lupus erythematosus. The decision was not taken due to any safety concern. At the time of ILLUMINATE 1 study, Tabalumab was not able to achieve the primary endpoint of the does and standard of care therapy. At the time of ILLUMINATE 2, a higher dose of Tabalumab met its endpoint easily. It was the first time when a lupus study had achieved this efficiency measure as an endpoint in a phase three trial. Overall data received in these studies did not meet the expectation levels for efficacy level of existing treatments. When it comes to the overall frequency of a similar adverse event in several patients of standard of care or Tabalumab, the results are not that accurate. LLY is looking forward to submitting the complete data for disclosure in any well-known and appropriate scientific venues.
On the basis of overall efficacy results from these two pivotal Phase 3 studies, LLY will not look forward to submitting the results of these studies to global regulators. Eli Lilly and Co (NYSE:LLY) wants to serve its clients in the best possible way; it will continue to do so. As far as current results are concerned, it will look to get in touch with good investigators and conclude these studies in such a way that they could be beneficial for patients. According to J. Anthony Ware, Senior Vice President, M.D., Product Development, LLY, the entire management team of LLY is extremely happy to see Tabalumab meets the specified criteria for improvement in the SRI-5 endpoint. At the same time, it is disappointed to see that overall results of these studies have not improved the state of patients.
